The prognostic factors for clinical N1b patients in thyroid papillary carcinoma

Yuksel, Ulvi Murat; Turanlı, Sevim; Acar, Yunus; Berberoğlu, Uğur

doi:10.4103/jcrt.jcrt_1011_16

Cited by 10 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, T stage classi cation not only included intrathyroidal PTCs, but also other parameters. Therefore, the signi cance of T stage in DFS may not be displayed, and this was in accordance with Yuksel UM et.al's study 14 .…”

Section: Discussionsupporting

confidence: 88%

See 1 more Smart Citation

Lower Collagen Area and Contralateral Lymph Node Metastasis Type Associated with Lower Disease-Free Survival in Thyroid Papillary Carcinoma

Dou

Tang

et al. 2020

Preprint

View full text Add to dashboard Cite

Objectives: To introducing a novel prognostic risk scheme which based on collagen area and lymph node metastasis type in thyroid papillary carcinoma (PTC).Method: Tumor collagen area and lymph node matastasis type as well as several other histomorphological factors with disease-free survival (DFS) were investigated in a corhort of 101 PTC patients. Results: Median follow-up time of DFS was 76 months(inter quartile range: 71–83 months). Low collagen area and contralateral lymph node matastasis type were associated with dismal patient disease-free survival (DFS) significantly. While tumors with high collagen area showed a mean DFS of 77.37 months, gradually decreased to 76.53 months for tumors with moderate collagen area and to 66.67 months for tumors with low collagen area (p =0.028). Negtive, central and ipsilateral lymph node metastasis showed mean DFS of 72.72, 74.8 and 72.81 months respectively, decreased to 62.17 months with bilateral lymph node metastasis and 59.43 months with contralateral lymph node metastasis (p=0.029). In the cohort, uinivariate statistical analysis of the novel risk scheme revealed that the hazard ratio (HR) for DFS was 5.18 for R2 and 15.53 for R3 tumors compared to R1 PTC (p=0.003). Disease free survival dropped from 77.74 months for R1 tumors to 68.7 months for R2 and 56.38 months for R3. Multivariate statistical analysis of the novel risk scheme revealed that the HR for DFS was 3.259 (95% confident interval [CI] 1.122–9.469, p=0.03).Conclusion: Our novel risk algorithm incorporating tumor collagen area and lymph node matastasis type allows strongly prognostic stratification of PTC. We suggest this risk algorithm as a morphology-based parameter for the routine diagnostic assessment of this tumor entity.

show abstract

Section: Discussionsupporting

confidence: 88%

“…Bilateral and contralateral lymph node metastasis type were signi cantly associated with shortened DFS (p = 0.029). This was inaccordance with Yuksel, U. M.'s study 14 . Two operative methods were included in this study: total thyroidectomy with lymph node dissection and subtotal thyroidectomy with lymph node dissection.…”

Section: Discussioncontrasting

confidence: 72%

Lower Collagen Area and Contralateral Lymph Node Metastasis Type Associated with Lower Disease-Free Survival in Thyroid Papillary Carcinoma

Dou

Tang

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Several studies have investigated cutoff values of LNR to verify its prognostic ability in patients with N1b PTC. Yuksel et al reported that a cutoff of 0.21 for LNR was a predictor of DFS in patients with N1b PTC [ 31 ]. Lee et al revealed that a cutoff of 0.218 for LNR was a predictor of recurrence in patients with N1b PTC [ 32 ].…”

Section: Discussionmentioning

confidence: 99%

Central Lymph Node Ratio Predicts Recurrence in Patients with N1b Papillary Thyroid Carcinoma

Kang

Kim

Park

et al. 2022

Cancers

View full text Add to dashboard Cite

The lymph node ratio (LNR) indicates the number of metastatic lymph nodes (LNs) to the total number of LNs. The prognostic value of LNR in papillary thyroid carcinoma (PTC) and other solid tumors is known. This study aimed to investigate the relationship between LNR and disease-free survival (DFS) in patients with PTC with lateral LN metastases (N1b PTC). A total of 307 patients with N1b PTC who underwent total thyroidectomy and therapeutic central and lateral LN dissection were retrospectively analyzed. The DFS and recurrence risk in the patients with LNR, central-compartment LNR (CLNR), and lateral-compartment LNR (LLNR) were compared. The mean follow-up duration was 93.6 ± 19.9 months. Eleven (3.6%) patients experienced recurrence. Neither LNR nor LLNR affected the recurrence rate in our analysis (p = 0.058, p = 0.106, respectively). However, there was a significant difference in the recurrence rates between the patients with low and high CLNR (2.1% vs. 8.8%, p = 0.017). In the multivariate analysis, CLNR ≥ 0.7 and perineural invasion were independent predictors of tumor recurrence. High CLNR was associated with an increased risk of recurrence, and was shown to be a significant predictor of prognosis in patients with N1b PTC.

show abstract

“…Papillary thyroid carcinoma (PTC), with increasing incidence in recent years, is the most prevalent type of thyroid carcinoma [1][2][3]. As treatments of PTC have been greatly improved, most patients with PTC can be treated by properly applied surgery and postoperative regular thyroxine suppressive therapy alone or with postoperative radioactive iodine therapy [4][5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Deltex3 inhibits Epithelial Mesenchymal Transition in Papillary Thyroid Carcinoma via promoting ubiquitination of XRCC5 to regulate the AKT signal pathway

Wang¹,

Huang²,

Liu³

et al. 2021

J. Cancer

View full text Add to dashboard Cite

The prognostic factors for clinical N1b patients in thyroid papillary carcinoma

Cited by 10 publications

References 23 publications

Lower Collagen Area and Contralateral Lymph Node Metastasis Type Associated with Lower Disease-Free Survival in Thyroid Papillary Carcinoma

Lower Collagen Area and Contralateral Lymph Node Metastasis Type Associated with Lower Disease-Free Survival in Thyroid Papillary Carcinoma

Central Lymph Node Ratio Predicts Recurrence in Patients with N1b Papillary Thyroid Carcinoma

Deltex3 inhibits Epithelial Mesenchymal Transition in Papillary Thyroid Carcinoma via promoting ubiquitination of XRCC5 to regulate the AKT signal pathway

Contact Info

Product

Resources

About